Company / Financials
Larimar Therapeutics, Inc. Financials
FY2014-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$0
FY2019
Net Income
-$52.0M
FY2019 · +10.1% YoY
Profit Margin
-
FY2019 · net income / revenue
ROE
-55.8%
FY2019 · return on equity
Total Assets
$80.7M
FY2019
Total Debt
-
FY2019
Equity
$93.3M
FY2019
ROA
-64.4%
FY2019 · return on assets
Statement paths
Financial highlights
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -4.64 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$0Net Income HistoryProfit after all expenses and taxes-$52.0M+10.1% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$53.0M+9.0% YoYSG&A Expense HistorySelling, general, and administrative expenses$12.2M-33.5% YoYR&D Expense HistoryResearch and development spending$40.8M+2.3% YoYInterest Expense HistoryCost of borrowing and debt obligations$165.0K-68.8% YoYIncome Tax HistoryTotal income tax expense$0EPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$1.90+10.4% YoYShares Outstanding HistoryWeighted average diluted shares outstanding37.3M+35.6% YoYTotal Assets HistoryTotal value of all assets owned$80.7M-33.7% YoY